Status:
ACTIVE_NOT_RECRUITING
Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
Lead Sponsor:
University of Leipzig
Conditions:
Dyspnea
Eligibility:
All Genders
18-90 years
Brief Summary
Invasive diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with unexplained dyspnea NYHA II-III compared to other diagnostic tools
Detailed Description
Multiple diagnostic tests, including stress tests and the invasive conduction of left ventricular pressure-volume loops via conductance catheter (as gold standard) will be performed in patients with u...
Eligibility Criteria
Inclusion
- dyspnea NYHA II-III
- age 18-90 years
- left ventricular ejection fraction ≥ 50%
- ability to give informed consent
Exclusion
- unstable cardiac disease with acute decompensation
- documented former LVEF ≤ 40%
- heart valve disease with medium or high grade insufficiency or stenosis
- coronary heart disease with hemodynamically relevant coronary stenosis
- specific cardiomyopathia
- acute or chronic cardiac inflammation (myocarditis, pericarditis)
- former heart transplantation
- relevant pulmonary disease (e.g. COPD) assumably causing the dyspnea
- FEV1/VC \< 70%
- hemoglobin \< 5 mmol/l
- pregnant or nursing women
- contraindication for one of the diagnostic tests
Key Trial Info
Start Date :
September 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04688905
Start Date
September 9 2020
End Date
August 30 2026
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Leipzig
Leipzig, Saxony, Germany, 04103